All Stories

  1. Production of human elafin by genetically modified Lactococcus lactis: evaluation of its anti-inflammatory effects in a murine model of intestinal mucositis
  2. Synbiotic Microencapsulation of Lactobacillus Strains from Mexican Fermented Beverages for Enhanced Probiotic Functionality
  3. Microencapsulation and Probiotic Characterization of Lactiplantibacillus plantarum LM-20: Therapeutic Application in a Murine Model of Ulcerative Colitis
  4. Unraveling the gut-skin axis in atopic dermatitis: exploiting insights for therapeutic strategies
  5. The food grade bacteriumLactobacillus helveticus VEL12193promotes autophagy by releasing membrane vesicles
  6. Probiotic Activity of Lactic Acid Bacteria Isolated from Traditional Mexican Fermented Beverages
  7. Use of Rgg quorum-sensing machinery to create an innovative recombinant protein expression system in Streptococcus thermophilus
  8. Importance of Probiotics in Fish Aquaculture: Towards the Identification and Design of Novel Probiotics
  9. Long-term intake of Lactobacillus helveticus enhances bioavailability of omega-3 fatty acids in the mouse retina
  10. Impact of Oral Administration of Lactiplantibacillus plantarum Strain CNCM I−4459 on Obesity Induced by High-Fat Diet in Mice
  11. Beneficial Effects of Lactobacilli Species on Intestinal Homeostasis in Low-Grade Inflammation and Stress Rodent Models and Their Implication in the Modulation of the Adhesive Junctional Complex
  12. Faecalibacterium: a bacterial genus with promising human health applications
  13. Host-microbe interactions mediate doramectin-promoted metabolic reprogramming of CD8+ T-cells and amplify antitumor immunity
  14. Lactic Fermentation of Broccoli (Brassica oleracea var. italica) to Enhance the Antioxidant and Antiproliferative Activities
  15. Use of genetically modified lactic acid bacteria and bifidobacteria as live delivery vectors for human and animal health
  16. Strategies for the Identification and Assessment of Bacterial Strains with Specific Probiotic Traits
  17. Effects of a Modern Kefir on Conditions Associated with Moderate Severe Spastic Quadriparesis Cerebral Palsy
  18. Functional Foods, Nutraceuticals and Probiotics: A Focus on Human Health
  19. Looking inside Mexican Traditional Food as Sources of Synbiotics for Developing Novel Functional Products
  20. Genome Sequence and Assessment of Safety and Potential Probiotic Traits of Lactobacillus johnsonii CNCM I-4884
  21. Probiotics against Viral Infections: Current Clinical Trials and Future Perspectives
  22. Probiotics and Trained Immunity
  23. Age and Giardia intestinalis Infection Impact Canine Gut Microbiota
  24. Bioactive Compounds in Food as a Current Therapeutic Approach to Maintain a Healthy Intestinal Epithelium
  25. Antioxidant and Anti-Inflammatory Properties of Probiotic Candidate Strains Isolated during Fermentation of Agave (Agave angustifolia Haw)
  26. Anti-microbiota vaccines modulate the tick microbiome in a taxon-specific manner
  27. Role of Gut Microbiota and Probiotics in Colorectal Cancer: Onset and Progression
  28. Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease
  29. Modulation of the PI3K/Akt/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response
  30. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3
  31. Identification of sulfur components enhancing the anti-Candida effect of Lactobacillus rhamnosus Lcr35
  32. Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis
  33. Protective Effect of Glycomacropeptide on Food Allergy with Gastrointestinal Manifestations in a Rat Model through Down-Regulation of Type 2 Immune Response
  34. Retraction Note to: Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer
  35. The Administration Matrix Modifies the Beneficial Properties of a Probiotic Mix of Bifidobacterium animalis subsp. lactis BB-12 and Lactobacillus acidophilus LA-5
  36. Evaluation of the Probiotic Properties and the Capacity to Form Biofilms of Various Lactobacillus Strains
  37. Gut Microbiota Abrogates Anti-α-Gal IgA Response in Lungs and Protects against Experimental Aspergillus Infection in Poultry
  38. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes
  39. Butyrate mediates anti-inflammatory effects of Faecalibacterium prausnitzii in intestinal epithelial cells through Dact3
  40. Targeting Melanoma Hypoxia with the Food-Grade Lactic Acid Bacterium Lactococcus Lactis
  41. Probiotics as Anti-Giardia Defenders: Overview on Putative Control Mechanisms
  42. Probiotic Properties of Lactobacillus Strains Isolated from Table Olive Biofilms
  43. Abdominoplasty in Hemodialysis Patients Before Transplant
  44. Oral delivery of pancreatitis‐associated protein by Lactococcus lactis displays protective effects in dinitro‐benzenesulfonic‐acid‐induced colitis model and is able to modulate the composition of the microbiota
  45. From Probiotics to Psychobiotics: Live Beneficial Bacteria Which Act on the Brain-Gut Axis
  46. Phosphatidylglycerols are novel lipids dysregulated in obesity
  47. The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response
  48. Anti-tumoral Effects of Recombinant Lactococcus lactis Strain Secreting IL-17A Cytokine
  49. Elucidating the Immune-Related Mechanisms by Which Probiotic Strain Lactobacillus casei BL23 Displays Anti-tumoral Properties
  50. A New Bifidobacteria Expression SysTem (BEST) to Produce and Deliver Interleukin-10 in Bifidobacterium bifidum
  51. M cell–targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing L. lactis
  52. Gut microbiome modulation during treatment of mucositis with the dairy bacterium Lactococcus lactis and recombinant strain secreting human antimicrobial PAP
  53. Live bacterial biotherapeutics in the clinic
  54. Latency and amplitude changes in cognitive event related potentials due to hemodialysis
  55. Increased gut permeability in cancer cachexia: mechanisms and clinical relevance
  56. A Versatile New Model of Chemically Induced Chronic Colitis Using an Outbred Murine Strain
  57. Searching for the Bacterial Effector: The Example of the Multi-Skilled Commensal Bacterium Faecalibacterium prausnitzii
  58. Bile Salt Hydrolase Activities: A Novel Target to Screen Anti-Giardia Lactobacilli?
  59. Bile-Salt-Hydrolases from the Probiotic Strain Lactobacillus johnsonii La1 Mediate Anti-giardial Activity in Vitro and in Vivo
  60. Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?
  61. Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer
  62. New Insights into the Diversity of the Genus Faecalibacterium
  63. Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold?
  64. Functional Characterization of Novel Faecalibacterium prausnitzii Strains Isolated from Healthy Volunteers: A Step Forward in the Use of F. prausnitzii as a Next-Generation Probiotic
  65. Use of Wild Type or Recombinant Lactic Acid Bacteria as an Alternative Treatment for Gastrointestinal Inflammatory Diseases: A Focus on Inflammatory Bowel Diseases and Mucositis
  66. Beneficial effects on host energy metabolism of short-chain fatty acids and vitamins produced by commensal and probiotic bacteria
  67. Contribution of sortase SrtA2 to Lactobacillus casei BL23 inhibition of Staphylococcus aureus internalization into bovine mammary epithelial cells
  68. Secretion of biologically active pancreatitis-associated protein I (PAP) by genetically modified dairy Lactococcus lactis NZ9000 in the prevention of intestinal mucositis
  69. Anti-cancer effect of lactic acid bacteria expressing antioxidant enzymes or IL-10 in a colorectal cancer mouse model
  70. The use of Mexican xaxtle as leavening agent in Italian straight dough bread making to produce pulque bread
  71. Screening of probiotic strains to improve visceral hypersensitivity in irritable bowel syndrome by using in vitro and in vivo approaches
  72. Assessment of the safety of Levilactobacillus brevis CNCM I-5321, a probiotic candidate strain isolated from pulque with anti-proliferative activities
  73. Erratum to: Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model
  74. Evaluation of the biosafety of recombinant lactic acid bacteria designed to prevent and treat colitis
  75. Metagenomic analysis of the human microbiome
  76. Brief cognitive behavioural intervention for depression and anxiety symptoms improves quality of life in chronic haemodialysis patients
  77. A large scale in vitro screening of Streptococcus thermophilus strains revealed strains with a high anti-inflammatory potential
  78. Bifidobacterium animalis ssp. lactis CNCM-I2494 Restores Gut Barrier Permeability in Chronically Low-Grade Inflamed Mice
  79. A new lactobacilliin vivoexpression system for the production and delivery of heterologous proteins at mucosal surfaces
  80. Gnotobiotic Rodents: An In Vivo Model for the Study of Microbe–Microbe Interactions
  81. Expression of fibronectin binding protein A (FnBPA) from Staphylococcus aureus at the cell surface of Lactococcus lactis improves its immunomodulatory properties when used as protein delivery vector
  82. Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models
  83. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer
  84. The secreted l-arabinose isomerase displays anti-hyperglycemic effects in mice
  85. Protective effect of TSLP delivered at the gut mucosa level by recombinant lactic acid bacteria in DSS-induced colitis mouse model
  86. Drying process strongly affects probiotics viability and functionalities
  87. Identification of novel anti-inflammatory probiotic strains isolated from pulque
  88. Engineering Lactic Acid Bacteria and Bifidobacteria for Mucosal Delivery of Health Molecules
  89. Identification of an anti-inflammatory protein fromFaecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease
  90. Identification of Metabolic Signatures Linked to Anti-Inflammatory Effects of Faecalibacterium prausnitzii
  91. Intranasal administration with recombinant Lactococcus lactis expressing heme oxygenase-1 reduces hyperoxia-induced lung inflammation in rat pups
  92. Effect of iron on the probiotic properties of the vaginal isolate Lactobacillus jensenii CECT 4306
  93. Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model
  94. Milk Fermented with a 15-Lipoxygenase-1-Producing Lactococcus Lactis Alleviates Symptoms of colitis in a Murine Model
  95. Serine protease inhibitors protect better than IL-10 and TGF-β anti-inflammatory cytokines against mouse colitis when delivered by recombinant lactococci
  96. Construction d’un vecteur d’expression chez Lactococcus lactis basée sur la production d’une protéine ancrée de Papillomavirus humain 16 E2/E7
  97. Lactobacillus rhamnosusCNCM I-3690 and the commensal bacteriumFaecalibacterium prausnitziiA2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice
  98. Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models
  99. The Indigenous Microbiota and its Potential to Exhibit Probiotic Properties
  100. Protective Effects of Lactococci Strains Delivering Either IL-10 Protein or cDNA in a TNBS-induced Chronic Colitis Model
  101. Selection of Anti-Inflammatory Lactic Acid Bacteria From A Pool of Yoghurt Starter Cultures
  102. Gut ecosystem: how microbes help us
  103. The Dual Role of MAPK Pathway in the Regulation of Intestinal Barrier
  104. Tu1778 Faecalibacterium prausnitzii Prevents Irritable Bowel Syndrome-Like Symptoms in Both Murine Low Grade Chronic Inflammation and Acute Stress Models
  105. Tu1746 Faecalibacterium prausnitzii Provides Host Beneficial Metabolic Profile During Inflammation
  106. 83 Identification of an Anti-Inflammatory Protein From Faecalibacterium prausnitzii, a Deficient Commensal Bacteria Implicated in Crohn's Disease
  107. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation
  108. Novel Role of the Serine Protease Inhibitor Elafin in Gluten-Related Disorders
  109. The Commensal Bacterium Faecalibacterium prausnitzii Is Protective in DNBS-induced Chronic Moderate and Severe Colitis Models
  110. The role of metagenomics in understanding the human microbiome in health and disease
  111. Ecology and metabolism of the beneficial intestinal commensal bacteriumFaecalibacterium prausnitzii
  112. Genetically Engineered Immunomodulatory Streptococcus thermophilus Strains Producing Antioxidant Enzymes Exhibit Enhanced Anti-Inflammatory Activities
  113. Development of a Stress-Inducible Controlled Expression (SICE) system in Lactococcus lactis for the production and delivery of therapeutic molecules at mucosal surfaces
  114. Nuclease A (Gbs0661), an extracellular nuclease ofStreptococcus agalactiae, attacks the neutrophil extracellular traps and is needed for full virulence
  115. Engineering lactococci and lactobacilli for human health
  116. Faecalibacterium prausnitzii and human intestinal health
  117. Mucosal targeting of therapeutic molecules using genetically modified lactic acid bacteria: an update
  118. Tu1988 Impact of the Commensal Bacterium Faecalibacterium prausnitzii in a Non Active Inflammation Murine Model
  119. Implications of the human microbiome in inflammatory bowel diseases
  120. Erratum to: Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface
  121. Role of commensal and probiotic bacteria in human health: a focus on inflammatory bowel disease
  122. Anti-Inflammatory Properties of Genetically Modified Lactic Acid Bacteria
  123. Contributors
  124. Identification of One Novel Candidate Probiotic Lactobacillus plantarum Strain Active against Influenza Virus Infection in Mice by a Large-Scale Screening
  125. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface
  126. Food-Grade Bacteria Expressing Elafin Protect Against Inflammation and Restore Colon Homeostasis
  127. Functional Analysis of the Lactobacillus casei BL23 Sortases
  128. Inactivation of theybdDGene in Lactococcus lactis Increases the Amounts of Exported Proteins
  129. Importance of Commensal and Probiotic Bacteria in Human Health
  130. Mo1855 Oral Treatment With Elafin-Recombinant Probiotics Improves Visceral Pain and Hypersensitivity in a Model of Irritable Bowel Syndrome (IBS)
  131. Mo2015 Food-Grade Lactic Acid Bacteria Expressing Elastase Inhibitors Protect From Intestinal Inflammation in Acute and Chronic Models of Colitis in Mice
  132. Sa2060 Gnotobiotic Mice, a Promising Tool to Better Understand the Anti-Inflammatory Effects of Faecalibacterium prausnitziï?
  133. Sa2061 Protective and Curative Effect of Faecalibacterium prausnitzii in a Chronic DNBS-Induced Murine Colitis
  134. Tu1842 Elastolytic Balance in IBD: the Elastase Inhibitor Elafin Prevents Loss of Barrier Function and Cytokines Release by Human Intestinal Epithelial Cells in IBD Conditions
  135. Anti-inflammatory properties of dairy lactobacilli
  136. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection
  137. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment
  138. Use of superoxide dismutase and catalase producing lactic acid bacteria in TNBS induced Crohn's disease in mice
  139. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines
  140. Variations of N-acetylation level of peptidoglycan do not influence persistence of Lactococcus lactis in the gastrointestinal tract
  141. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice
  142. Perspectives for the development of human papillomavirus vaccines and immunotherapy
  143. Utilisation des bactéries lactiques comme vecteurs vaccinaux
  144. Protective Effects of a Heme Oxygenase-1-Secreting Lactococcus lactis on Mucosal Injury Induced by Hemorrhagic Shock in Rats
  145. Lactococcus lactisas a live vector for mucosal delivery of therapeutic proteins
  146. Development of Mucosal Vaccines Based on Lactic Acid Bacteria
  147. Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium
  148. Allergy Therapy by Intranasal Administration with Recombinant Lactococcus lactis Producing Bovine β-Lactoglobulin
  149. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients
  150. Production of biologically active CXC chemokines by Lactococcus lactis: Evaluation of its potential as a novel mucosal vaccine adjuvant
  151. Anti-inflammatory Properties of Lactic Acid Bacteria: Current Knowledge,Applications and Prospects
  152. Intragastric administration with recombinant Lactococcus lactis producing heme oxygenase-1 prevents lipopolysaccharide-induced endotoxemia in rats
  153. Production of biological active murine IFN-γ by recombinant Lactococcus lactis
  154. Consumption of Camembert cheese stimulates commensal enterococci in healthy human intestinal microbiota
  155. Current Prophylactic and Therapeutic Uses of a Recombinant Lactococcus lactis Strain Secreting Biologically Active Interleukin-12
  156. Lactococcus lactis, an Efficient Cell Factory for Recombinant Protein Production and Secretion
  157. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria
  158. Effects of Intranasal Administration of a Leptin-Secreting Lactococcus lactis Recombinant on Food Intake, Body Weight, and Immune Response of Mice
  159. Intranasal Coadministration of Live Lactococci Producing Interleukin-12 and a Major Cow's Milk Allergen Inhibits Allergic Reaction in Mice
  160. Anti-inflammatory effects of Lactobacillus casei BL23 producing or not a manganese-dependant catalase on DSS-induced colitis in mice
  161. Antimicrobial Activity of Divercin RV41 Produced and Secreted by Lactococcus lactis
  162. Construction and characterization of a Lactococcus lactis strain deficient in intracellular ClpP and extracellular HtrA proteases
  163. Des bactéries pour prévenir et traiter le cancer du col de l’utérus induit par le papillomavirus humain de type 16
  164. Immunomodulatory effects of IL-12 secreted by Lactococcus lactis on Th1/Th2 balance in ovalbumin (OVA)-induced asthma model mice
  165. Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis
  166. A Novel Mucosal Vaccine Based on Live Lactococci Expressing E7 Antigen and IL-12 Induces Systemic and Mucosal Immune Responses and Protects Mice against Human Papillomavirus Type 16-Induced Tumors
  167. Improvement of bovine ß-lactoglobulin production and secretion by Lactococcus lactis
  168. Cell-surface display of E7 antigen from human papillomavirus type-16 inLactococcus lactisand inLactobacillus plantarumusing a new cell-wall anchor from lactobacilli
  169. An inducible surface presentation system improves cellular immunity against human papillomavirus type 16 E7 antigen in mice after nasal administration with recombinant lactococci
  170. Article
  171. Mice immunization with live lactococci displaying a surface anchored HPV-16 E7 oncoprotein
  172. Controlled intra- or extracellular production of staphylococcal nuclease and ovine omega interferon inLactococcus lactis
  173. Fusion to a Carrier Protein and a Synthetic Propeptide Enhances E7 HPV-16 Production and Secretion in Lactococcus lactis
  174. Intranasal Immunization with Recombinant Lactococcus lactis Secreting Murine Interleukin-12 Enhances Antigen-Specific Th1 Cytokine Production
  175. Loss of Restriction Site DdeI, used for Avian Molecular Sexing, in Oreophasis derbianus
  176. Controlled Production of Stable Heterologous Proteins in Lactococcus lactis
  177. Molecular sexing of monomorphic endangeredArabirds
  178. Production of Human Papillomavirus Type 16 E7 Protein in Lactococcus lactis